Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Closes 18 September, 2024
Issue Pre-order formJournal: Current Pharmaceutical Design
Guest editor(s):Dr. Sidharth Mehan
Introduction
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and pharmaceutical companies alike. By examining the latest advancements, emerging technologies, and unresolved issues, this issue seeks to foster a deeper understanding of the complexities involved in managing neurological dysfunctions.
Keywords
Neuropharmacology, Neurological disorders, Drug delivery, Precision medicine, Biomarkers, Clinical trials, Neuroethics , Innovation